25 February 2026

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Transaction Update & Intention to delist from the Main Market

Roquefort Therapeutics plc (LSE:ROQ), the Main Market listed biotech company, is pleased to announce the proposed transaction with Coiled Therapeutics, Inc. ("Coiled USA") and A2A Pharmaceuticals, Inc. ("A2A Pharma"), pursuant to which the Company will acquire the worldwide exclusive rights to AO-252, a drug candidate that binds to TACC3 for the treatment of cancers with unmet medical needs is nearing completion (the "Acquisition") which is conditional on the admission of the Company's issued and to be issued share capital being admitted to the AIM market of London Stock Exchange ("AIM Market") ("Admission").

The Company and its professional advisers are currently finalising documentation relating to the equity fundraise which is being undertaken in conjunction with the Acquisition (the "Fundraise"), along with the Company's AIM Admission Document and Notice of General Meeting, which is expected to be published in the coming days (see below) (the, Fundraise, Acquisition and Admission together referred to as the "Transaction").

Intention to delist from the Main Market

In conjunction with the Transaction, the Company announces its intention to cancel the listing of the Company's ordinary shares on the Equity Shares (Transition) category of the Official List of the Financial Conduct Authority ("FCA") and to cancel the trading of its ordinary shares on the Main Market of the London Stock Exchange (the "Delisting").

As a company listed on the Equity Shares (Transition) category, the Company is not required to obtain the approval of its shareholders for the Delisting but is required under UK Listing Rule 21.2.17 to give at least 20 business days' notice of the intended cancellation.

Accordingly, the Company has requested that: (i) the FCA cancel the listing of its ordinary shares on the Official List of the FCA; and (ii) the London Stock Exchange cancels the admission to trading of the ordinary shares on the Main Market for listed securities of the London Stock Exchange.

It is anticipated that the Delisting will become effective in not less than 20 business days. Full details regarding the specific timing of the Delisting, the Company's proposed readmission to the AIM Market, and the completion of the Transaction, will be provided shortly when the Company announces the publication of its AIM Admission Document.

Note

Further information regarding the Transaction, AO-252 and the AO-252 Licence Agreement is set out in the Company's RNS announcements dated 8 September 2025, 16 October 2025, 18 November 2025 and 12 December 2025.

Regulatory Information

This Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 ("UK MAR").

ENDS

Enquiries:

LEI: ‎254900P4SISIWOR9RH34

For further information on Roquefort Therapeutics, please visit www.roquefortplc.com 

About Coiled USA

Coiled USA is a clinical stage oncology company and is a spin-out of A2A Pharma. Coiled USA holds the exclusive worldwide rights to AO-252, a novel, brain-penetrant small molecule inhibitor designed to disrupt TACC3 protein-protein interactions.  Coiled USA has advanced the AO-252 program through pre-clinical development and IND approval and commenced Phase I trials in the USA (trials ID: NCT06136884).  Coiled USA is actively enrolling patients to test for safety and efficacy in patients whose cancer has progressed on other treatments.

About A2A Pharma

A2A Pharma is a private, company that uses proprietary computational systems, including generative AI with its SCULPT™ platform to accelerate the development of novel drug alternatives for life threatening diseases like cancer.  This enables a more efficient process than traditional trial and error approaches to drug discovery. 

A2A Pharma aims to develop therapies to early clinical stages and then spin them out into standalone entities to progress them through clinical development.  In 2018, A2A Pharma spun out its MLL-Menin program to Biomea Fusion, Inc. ("Biomea Fusion"), a company that completed an IPO on Nasdaq in 2021 raising US$153 million and listing with a market capitalisation of US$464 million.  Post-IPO Biomea Fusion's market capitalisation reached a peak of over US$1 billion.

Further information on A2A Pharma can be found at: https://www.a2apharma.com/